Miriam E. Tucker is a writer and journalist specializing in medicine and health. She has been living with type 1 diabetes since 1973, giving her a unique perspective on the topics she covers. Miriam's work has been featured in various publications, including Guidelines Co, MDEdge, Knowledia, Medscape, and The diaTribe Foundation.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Miriam E. Tucker's coverage primarily focuses on health, healthcare & pharmaceuticals, and scientific topics with an emphasis on citing data. She seems to be interested in research findings and regulatory updates within the medical field.
To effectively reach out to Miriam, consider providing her with access to authoritative sources or researchers who can offer insights into the latest developments in diabetes, medical research methodologies and results, obesity treatments, thyroid disease management strategies, as well as advancements in bariatric surgery procedures.
As she cites data extensively in her articles, ensure that any pitches provide robust evidence-based information or refer to credible studies related to the specific topics covered by Miriam.
This information evolves through artificial intelligence and human feedback. Improve this profile .
TOPLINE: People diagnosed with type 2 diabetes (T2D) at age < 40 years had a high risk for incident diabetes-related complications, excess
By: Miriam E. Tucker
January 2, 2024 | Rheumatology News FROM AN NIH RESEARCH CONFERENCE
TOPLINE: The Joint British Diabetes Societies for Inpatient Care group and the Diabetes Technology Network have published guidelines on the use of technology to support diabetes care in hospital.
The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain conditions.
A new analysis from Novo Nordisk’s SELECT trial points to the potential for cost savings.
SAN ANTONIO, Texas — An upcoming document will entirely reframe obesity as a “condition of excess adiposity” that constitutes a disease called “clinical obesity” when related tissue and organ abnormalities are present.
A document to be published in Lancet Diabetes & Endocrinology will redefine obesity as a condition of excess adiposity, and “clinical obesity” as a disease.
TOPLINE: Nearly all patients reported receiving instructions to take levothyroxine (LT4) while fasting, but a third did not adhere to this.
SAN ANTONIO – Once-weekly tirzepatide (Zepbound) reduced the risk for progression from prediabetes to type 2 diabetes (T2D) by more than 90% at 3
A document to be published in Lancet Diabetes & Endocrinology will redefine obesity as a condition of excess adiposity, and "clinical obesity" as a disease.
(833) 317-6278 
